Zhongguancun AI new drug research and development platform was completed to help speed up biopharmaceutical development

On the afternoon of December 19, the Zhongguancun AI new drug research and development platform jointly initiated and constructed by Zhongguancun Life Science Park and Kaojing (Beijing) Biotechnology Co., Ltd. held an inauguration ceremony at Beijing Zhongguancun Life Science Park. The Paper (www.thepaper.cn) learned from the inauguration ceremony that the platform was officially launched in December 2020 and can help pharmaceutical companies quickly discover and screen drug targets, explore drug action mechanisms, and optimize specific antibodies. , which is also the first new drug research and development platform in China that combines artificial intelligence technology with biomedical technology.

"The research and development of biomedicine has entered the era of drug screening and design for specific biological effect targets." As the initiator of the Zhongguancun AI new drug research and development platform, Zhou Jing, founder of Kaojing Biotech, said that in recent years With the recent breakthroughs in various high-throughput detection technologies, the amount of genome, transcriptome, proteome and other data has increased exponentially, far exceeding the analysis capabilities of traditional statistical methods.

Zhou Ming believes that artificial intelligence technology has developed rapidly in recent years and has the ability to process massive medical data based on more powerful algorithms and computing power. Therefore, the research and development of innovative drugs has entered a data-based era. The era of intelligent development based on computer science and computing has brought new drugs and disease treatment options to mankind.

In fact, artificial intelligence has appeared in the top ten scientific breakthroughs published by Science magazine in the past two years.

On December 17 this year, "Science" announced the list of the top ten scientific breakthroughs in 2021. AlphaFold 2 and RoseTTA-fold, two technologies based on artificial intelligence technology to predict the structure of human proteins, ranked first. This AI technology accurately predicts the structure of almost all proteins expressed by humans.

On December 17, 2020, "Science" announced its selection of the top ten scientific breakthroughs of 2020. Among them, AlphaFold artificial intelligence accurately predicted the three-dimensional structure of proteins for the first time, with an accuracy comparable to that of cryo-electron microscopy. , X-ray crystallography and other experimental techniques. The researchers pointed out that since the precise shape of a protein determines its biochemical function, this new development can help researchers discover the pathogenesis of diseases and develop new drugs.

The Zhongguancun AI new drug research and development platform completed this time includes functional modules such as high-performance computing center, high-throughput automation equipment, and drug verification laboratories, which can realize data generation, algorithm training, and wet experiment verification of drugs. Discover the full process of working.

"In 2019, Beijing's artificial intelligence-related output value reached 170 billion yuan, and the number of artificial intelligence-related companies exceeded 1,500." Wang Wenli, general manager of Zhongguancun Life Science Park, introduced at the ceremony that the Zhongguancun AI New Drug Research and Development Platform With its unique location advantages, it can fully integrate artificial intelligence technology, biomedical R&D resources and clinical data resources, and widely empower domestic and foreign biotechnology companies through AI technology, greatly shortening the company's new drug research and development cycle and reducing research and development costs. , rapidly promote the growth of new drug research and development enterprises, and promote the high-quality development of the national pharmaceutical and health industry.